KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798
This study is recruiting at 6 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- August 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Hampshire · 1
- Dartmouth Hitchcock Medical Center ( Site 0016) · Lebanon, NH
North Dakota · 1
- Sanford Fargo Medical Center ( Site 0039) · Fargo, ND
Ohio · 1
- Ohio State University Comprehensive Cancer Center ( Site 0015) · Columbus, OH
Pennsylvania · 1
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010) · Philadelphia, PA
South Dakota · 1
- Sanford Cancer Center ( Site 0038) · Sioux Falls, SD
Texas · 1
- The University of Texas MD Anderson Cancer Center ( Site 0009) · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.